NHWK लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (6 Feb 2024 @ 02:28):

Stats
आज की मात्रा	161 222
औसत मात्रा	163 739
बाजार मूल्य	10.78M
EPS	$0 ( 2024-03-29 )
अगली कमाई की तारीख	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.202
ATR14	$0.0430 (13.71%)

Insider Trading

Date	Person	Action	Amount	type
2022-12-07	Wolf Jeffrey Alan	Buy	2 843 137	Stock Option (right to buy)
2022-12-07	Smith Edward B Iii	Buy	101 960	Stock Option (right to buy)
2022-12-07	Prendergast John K A	Buy	203 921	Stock Option (right to buy)
2022-12-07	Ostrander William L.	Buy	490 196	Stock Option (right to buy)
2022-12-07	Monahan John J	Buy	101 960	Stock Option (right to buy)

INSIDER POWER
100.00
Last 95 transactions
Buy: 24 129 486 \| Sell: 659 541

मात्रा सहसंबंध

लंबा: -0.20 (neutral)

छोटा: -0.48 (neutral)

Signal:(40.526) Neutral

NightHawk Biosciences, सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

NightHawk Biosciences, सहसंबंध - मुद्रा/वस्त्र

-0.39
( neutral )

-0.46
( neutral )

0.00
( neutral )

-0.50
( weak negative )

-0.39
( neutral )

0.05
( neutral )

NightHawk Biosciences, वित्तीय

Annual	2022
राजस्व:	$5.98M
सकल लाभ:	$-420 025 (-7.02 %)
EPS:	$-1.710

FY	2022
राजस्व:	$5.98M
सकल लाभ:	$-420 025 (-7.02 %)
EPS:	$-1.710

FY	2021
राजस्व:	$2.11M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-1.410

FY	2020
राजस्व:	$2.95M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-1.630

Financial Reports:

No articles found.

NightHawk Biosciences,

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.